Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen receptor (STAR)-T-cell therapy for relapsed/refractory acute myeloid leukemia.

Signal Transduct Target Ther · 2026 · PMC13226688 · PMID 42225613

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

We also analyzed the peak expansion of the LILRB4-expressing STAR-T cells in the responding and nonresponding patients, although this difference did not reach statistical significance (Fig. 4d ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.